Menopause Society Guidance on Hormone Therapy

Position statements read short, and short sentences hide their conditions. This note takes two sentences of published hormone therapy guidance and checks what each one covers and what it leaves out.

Two statements, side by side

The Australasian Menopause Society publishes a position statement with two sentences worth setting next to each other. One is about what hormone therapy treats. The other is about who it suits.

The first sentence reads: "Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture."

The second reads: "The benefits of hormone therapy outweigh the risks for most healthy symptomatic women who are aged younger than 60 years and within 10 years of menopause onset."

For background on the same subject, the Endocrine Society keeps a menopause page in its patient library.

What each sentence states

The first sentence names two symptom groups and one outcome. Vasomotor symptoms and the genitourinary syndrome of menopause are the symptom groups. Bone loss and fracture is the outcome. The Australasian Menopause Society calls hormone therapy the most effective treatment for the first two.

The second sentence is a balance statement, and it carries conditions. Benefits outweigh risks for "most" women, not all. They must be healthy and symptomatic. They must be younger than 60. They must be within 10 years of menopause onset.

What the sentences leave out

Neither sentence names a product, a brand, or a compounded blend. Both speak about hormone therapy as a category. A clinic that cites them for a custom formulation is stretching the wording past what it says.

The second sentence also says nothing for readers outside its conditions. Someone who is 62, or well past the ten-year mark, cannot read themselves into it. The text simply does not address them.

Marketing language and cited language

Cited language names its publisher, as this note has done. Marketing language borrows the authority of a phrase like "hormone therapy" without saying which statement backs which product.

When a description of a custom blend carries no named statement, mark it as unsupported and keep going. The U.S. Food and Drug Administration publishes questions and answers on compounding that are worth reading beside any such description.

The question to ask about age and timing

Ask which published statement, from which organization, applies to your age and your time since menopause onset. Then ask whether that same statement covers the specific product being offered.